Brought to you by 
BioMarin takes back PKU rights from Merck Serono
25 Sep 2017
Executive Summary
BioMarin Pharmaceutical Inc. reacquired rights to phenylketonuria (PKU) assets previously licensed to Merck KGAA’s Merck Serono SA. The transaction includes the marketed therapy Kuvan (sapropterin) and Phase III pegvaliase (Peg-Pal).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioMarin takes back PKU rights from Merck Serono
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice